YAP/TAZ axis was involved in the effects of metformin on breast cancer

References

• Flinn MA, Link BA, O'Meara CC. Upstream regulation of the Hippo-Yap pathway in cardiomyocyte regeneration. Semin Cell Dev Biol. 2020;100:11–19.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang R, Huang D, et al. Homoharringtonine exerts anti-tumor effects in hepatocellular carcinoma through activation of the Hippo pathway. Front Pharmacol. 2021;12:592071.
   PubMed Web of Science ®Google Scholar
• Kim MK, Jang JW, Bae SC. DNA binding partners of Yap/TAZ. BMB Rep. 2018;51(3):126–133.
   PubMed Web of Science ®Google Scholar
• Yeung B, Yu J, Yang X. Roles of the hippo pathway in lung development and tumorigenesis. Int J Cancer. 2016;138(3):533–539.
   PubMed Web of Science ®Google Scholar
• Cao L, Sun PL, Yao M, et al. Expression of YES-associated protein (Yap) and its clinical significance in breast cancer tissues. Hum Pathol. 2017;68:166–174.
   PubMed Web of Science ®Google Scholar
• Cheng S, Prieto-Dominguez N, Yang S, et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):661–669.
   PubMed Web of Science ®Google Scholar
• Crawford JJ, Bronner SM, Zbieg JR. Hippo pathway inhibition by blocking the Yap/TAZ-TEAD interface: a patent review. Expert Opin Ther Pat. 2018;28(12):867–873.
   PubMed Web of Science ®Google Scholar
• Feng Q, Guo P, Kang S, et al. High expression of TAZ/Yap promotes the progression of malignant melanoma and affects the postoperative survival of patients. Pharmazie. 2018;73(11):662–665.
   PubMed Web of Science ®Google Scholar
• Wei C, Wang Y, Li X. The role of hippo signal pathway in breast cancer metastasis. Onco Targets Ther. 2018;11:2185–2193.
   PubMed Web of Science ®Google Scholar
• Yao CB, Zhou X, Chen CS, et al. The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer. Yi Chuan. 2017;39(7):617–629.
   PubMedGoogle Scholar
• Yuan X, Wei W, Bao Q, et al. Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating Yap activity. Biomed Pharmacother. 2018;102:263–270.
   PubMed Web of Science ®Google Scholar
• Liu J, Li J, Li P, et al. DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression. J Cell Mol Med. 2019;23(1):512–521.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhi X, Zhou Z, et al. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis. 2012;33(1):59–67.
   PubMed Web of Science ®Google Scholar
• Yang N, Morrison CD, Liu P, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle. 2012;11(15):2922–2930.
   PubMed Web of Science ®Google Scholar
• Bronsveld HK, Jensen V, Vahl P, et al. Diabetes and breast cancer subtypes. PLoS One. 2017;12(1):e0170084.
   PubMed Web of Science ®Google Scholar
• Kim YS, Choi EA, Lee JW, et al. Metformin use reduced the overall risk of cancer in diabetic patients: a study based on the Korean NHIS-HEALS cohort. Nutr Metab Cardiovasc Dis. 2020;30(10):1714–1722.
   PubMed Web of Science ®Google Scholar
• Oh TJ, Yu JM, Min KW, et al. Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab J. 2019;43(3):276–286.
   PubMed Web of Science ®Google Scholar
• Tang GH, Satkunam M, Pond GR, et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2018;27(6):627–635.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008;8(6):501–505.
   PubMed Web of Science ®Google Scholar
• Kim J, Hyun HJ, Choi EA, et al. Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database. Gastric Cancer. 2020;23(6):1075–1083.
   PubMed Web of Science ®Google Scholar
• Liu H, Shi W, Jin Z, et al. Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017. BMC Cancer. 2021;21(1):459.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu N, Zhang SC, et al. New advances in targeted therapy for breast cancer. Zhonghua Zhong Liu Za Zhi. 2020;42(5):353–361.
   PubMedGoogle Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643.
   PubMed Web of Science ®Google Scholar
• García-Becerra R, Santos N, Díaz L, et al. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012;14(1):108–145.
   PubMed Web of Science ®Google Scholar
• Droog M, Beelen K, Linn S, et al. Tamoxifen resistance: from bench to bedside. Eur J Pharmacol. 2013;717(1-3):47–57.
   PubMed Web of Science ®Google Scholar
• Liu J, Li J, Chen H, et al. Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the hippo pathway. J Cell Mol Med. 2020;24(10):5786–5796.
   PubMed Web of Science ®Google Scholar
• Weadick B, Nayak D, Persaud AK, et al. EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1. Mol Cancer Ther. 2021;20(2):410–422.
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472–476.
   PubMed Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525–530.
   PubMed Web of Science ®Google Scholar
• Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883–4889.
   PubMed Web of Science ®Google Scholar
• Lourenco AR, Ban Y, Crowley MJ, et al. Differential contributions of pre- and Post-EMT tumor cells in breast cancer metastasis. Cancer Res. 2020;80(2):163–169.
   PubMed Web of Science ®Google Scholar
• Cao D, Zhu GY, Lu Y, et al. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting Yap/TAZ activity. Biomed Pharmacother. 2020;129:110462.
   PubMed Web of Science ®Google Scholar
• Agarwal G, Gabrani R. Antiviral peptides: identification and validation. Int J Pept Res Ther. 2021;27(1):149–168.
   PubMed Web of Science ®Google Scholar
• Elkashty OA, Ashry R, Elghanam GA, et al. Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas. Med Oncol. 2018;35(9):124.
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Matsuki E, Brentjens RJ, et al. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25–40.
   PubMed Web of Science ®Google Scholar
• Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534(7607):314–316.
   PubMed Web of Science ®Google Scholar